Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, October 02 2019 - 04:18
Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off
BAGSVÆRD, Denmark, October 2, 2019, /PRNewswire-AsiaNet/--

Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change 
company, today announced a collaboration on digital health solutions focusing 
on weight management and education, with the aim of improving the lives of 
people living with obesity. The collaboration follows a successful 8-month 
pilot that combined Noom's proven, science-backed behaviour change programmes 
with Novo Nordisk's more than 95 years of experience in helping people living 
with chronic diseases. This collaboration, as one of many ways Novo Nordisk is 
partnering to improve care, will make solutions for behaviour change and 
education available to people with obesity in the US.

"We are passionate about improving the lives of people with obesity and finding 
new solutions to support respectful and complete care, which includes lifestyle 
change and medical management," said Camilla Sylvest, Novo Nordisk executive 
vice president, Commercial Strategy & Corporate Affairs. "We believe that the 
combination of Noom's services, with Novo Nordisk's offerings to support people 
with obesity, will help educate and empower people with obesity to lose weight, 
keep it off – and live healthy lives." 

Noom's solutions seek to understand individual motivations and obstacles and 
use cutting-edge technology, including artificial intelligence, behavioural 
coaching by over 1,000 personal health coaches, data and wellness insights, to 
guide people towards sustainable change.

"Sustainable change can't happen in a vacuum, and those living with obesity who 
want to manage their weight are in need of personalised human coaching to help 
them change their habits, so they can lose weight for good," said Saeju Jeong, 
CEO and co-founder of Noom. "We've worked with the Novo Nordisk team for over a 
year and have engaged with over 4,000 people with obesity. We're enthused by 
the exciting feedback and know that by jointly testing and refining what works, 
we will continue to deliver much-needed, sustainable solutions and support, as 
part of a scientific, insight-driven treatment plan." 

About obesity

Obesity is a complex, chronic disease that is influenced by multiple aspects, 
including physiological, psychological, genetic, environmental and 
socioeconomic factors.1 It is associated with many serious health consequences2 
and decreased life expectancy.3 Obesity is not a life choice or simply a 
question about willpower4 and necessary help and support can be hard to find. 
There are few healthcare professionals trained in obesity care and patients 
often see their excess weight as something they should be able to solve on 
their own.5,6 Like any other chronic disease, the long-term management of 
obesity requires a full spectrum of treatment approaches, including lifestyle 
change and intervention, as well as pharmacotherapy or surgery.7 The global 
increase in the prevalence of obesity is a public health issue that has severe 
cost implications to healthcare systems.8,9 In 2016, 13% of adults, or 
approximately 650 million adults, were living with obesity worldwide.8
About Noom, Inc.

Noom is the world's leading behaviour change company, disrupting the weight 
loss and healthcare industries. By combining the power of artificial 
intelligence, mobile tech, and psychology with the empathy of over 1,000 
personal coaches, Noom helps people live healthier lives by changing their 
long-term habits. More than 50 million people have benefited from Noom's 
behaviour change courses, including its virtual diabetes prevention programme, 
which was the first of its kind to be recognised by the CDC. The Noom platform 
is already being used by leading healthcare and pharmaceutical companies to 
improve treatment outcomes for patients worldwide. The company is headquartered 
in New York City with offices in Seoul and Tokyo.
About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of 
innovation and leadership in diabetes care. This heritage has given us 
experience and capabilities that also enable us to help people defeat obesity, 
haemophilia, growth disorders and other serious chronic diseases. Headquartered 
in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries 
and markets its products in more than 170 countries. For more information, 
visit, Facebook, Twitter, LinkedIn, YouTube. 

Changing Obesity(TM) is our long-term commitment to improve the lives of people 
with obesity by changing how the world sees, prevents and treats obesity.
Further information

Media, Noom: NA 
Media, Novo Nordisk:		
Kristine Kruse Zeij	+45 3075 1987 		
Investors, Novo Nordisk:		
Peter Hugreffe Ankersen	+45 3075 9085 
Valdemar Borum Svarrer	+45 3079 0301 
Ann Sondermolle Rendbek	+45 3075 2253 
Kristoffer Due Berg (US) +1 609 235 2989
1. National Institutes of Health. Clinical Guidelines On The Identification, 
Evaluation, And Treatment Of Overweight And Obesity In Adults. Available at: Last accessed: April 
2. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related 
to obesity and overweight: a systematic review and meta-analysis. BMC Public 
Health. 2009; 9:1–20. 
3. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and 
cause-specific mortality in 900 000 adults: collaborative analyses of 57 
prospective studies. Lancet. 2009; 373:1083–1096. 
4. Rosen H. Is Obesity A Disease or A Behavior Abnormality? Did the AMA Get It 
Right? . Mo Med. 2014; 111:104–108. 
5. Kaplan L, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective 
Obesity Care: Results from the National ACTION Study. Obesity. 2018; 26:61–69. 
6. Caterson I, Alfadda A, Auerbach P, et al. Gaps to bridge: misalignment 
between perception, reality, and action in obesity. Diabetes Obes Metab. 
7. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the 
management of overweight and obesity in adults: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice 
Guidelines and The Obesity Society. Circulation. 2014; 129:S102–138. 
8. World Health Organization. Obesity and Overweight Factsheet no. 311. 
Available at: Last 
accessed: September 2019. 
9. Cawley J, Meyerhoefer C, Biener A, et al. Savings in Medical Expenditures 
Associated with Reductions in Body Mass Index Among US Adults with Obesity, by 
Diabetes Status. Pharmacoeconomics. 2015; 33:707–722.
Logo - 
Photo - 

SOURCE: Novo Nordisk